Modeling and Simulation - PK/PD Archives | Page 22 of 38

Publication

Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics

In drug development, considerable efforts are made to extrapolate from in vitro and preclinical findings…

CertaraOctober 1, 2014

Publication

Time Course of Bone Mineral Density Changes with Denosumab Compared with Other Drugs in Postmenopausal Osteoporosis: A Dose-response-based Meta-analysis

Our objective was to compare the time course of bone mineral density (BMD) changes at…

CertaraOctober 1, 2014

Publication

Cardiac Safety Research Consortium: Can the Thorough QT/QTc Study Be Replaced by Early QT Assessment in Routine Clinical Pharmacology Studies? Scientific Update and a Research Proposal for a Path Forward

The International Conference on Harmonization E14 guidance for the clinical evaluation of QT/QTc interval prolongation…

CertaraSeptember 1, 2014

Publication

Understanding the Effect of the HCV Polymerase Inhibitor Mericitabine on Early Viral Kinetics in the Phase 2 JUMP-C and PROPEL Studies

CertaraAugust 21, 2014

Knowledge Base

Adding a Placebo Component to Your PK/PD Model in Phoenix

PK/PD modeling is an exciting are of research in clinical pharmacology. Most often we try…

CertaraAugust 20, 2014

Knowledge Base

Bioanalytical Calibration Curves

At the request of a reader, I have decided to extend my series on bioanalysis…

CertaraAugust 12, 2014

Publication

Assessment of Tumor Growth Inhibition Metrics to Predict Overall Survival

Modeling and simulation is proposed to support drug development phase transitions in oncology. Longitudinal tumor-size…

CertaraAugust 1, 2014

Knowledge Base

Radiometric Analysis

One of the oldest methods used for the quantitation of drug molecules is radiometric analysis.…

CertaraJuly 29, 2014

Blog Knowledge Base

Understanding LC/MS/MS

The most common bioanalytical method in use today is LC/MS/MS, or liquid chromatography (LC) tandem…

CertaraJuly 15, 2014

Publication

Population Pharmacokinetic Analysis of Dutogliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor

Dutogliptin is a selective dipeptidyl peptidase-4 inhibitor shown to be efficacious and safe in patients…

CertaraJuly 14, 2014

Modeling and Simulation – PK/PD

Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics

Time Course of Bone Mineral Density Changes with Denosumab Compared with Other Drugs in Postmenopausal Osteoporosis: A Dose-response-based Meta-analysis

Cardiac Safety Research Consortium: Can the Thorough QT/QTc Study Be Replaced by Early QT Assessment in Routine Clinical Pharmacology Studies? Scientific Update and a Research Proposal for a Path Forward

Understanding the Effect of the HCV Polymerase Inhibitor Mericitabine on Early Viral Kinetics in the Phase 2 JUMP-C and PROPEL Studies

Adding a Placebo Component to Your PK/PD Model in Phoenix

Bioanalytical Calibration Curves

Assessment of Tumor Growth Inhibition Metrics to Predict Overall Survival

Radiometric Analysis

Understanding LC/MS/MS

Population Pharmacokinetic Analysis of Dutogliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor

Newsletter sign up

Quick links

Solutions

Contact